Roche gets green light to build new office high-rise

Basel, 25 February 2011

Roche announced today that it has received the planning permission from the City of Basel Building Inspectorate for Building 1, its new office high-rise. The company has thus been given the green light for construction of the new building. The new office high-rise will enable Roche to bring together at its site in Grenzacherstrasse some 2,000 employees whose offices are currently spread across the city of Basel.

“We are delighted that we now have the go-ahead to start construction”, said Matthias M. Baltisberger, Head of Roche’s Basel site. “Building 1 is a clear commitment of Roche to the Basel site as its corporate headquarters. We will create attractive workplaces that are conducive to dialogue and exchange, and offer a top-quality infrastructure to our employees.”

Excavation work on the foundation pit will start in Grenzacherstrasse in March 2011, while shell construction will take place between 2012 and the end of 2014. Interior fit-out work will take place simultaneously, starting in 2013. It is planned to move into the building at the end of 2015.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: